Literature DB >> 8750848

HLA expression and tumor-infiltrating immune cells in uveal melanoma.

I de Waard-Siebinga1, C G Hilders, B E Hansen, J L van Delft, M J Jager.   

Abstract

BACKGROUND: In uveal melanoma, both the amount of tumor-infiltrating cells and the level of expression of HLA antigens are quite variable. We hypothesized that low levels of HLA expression lead to a lack of antigen presentation, which might prevent proper immunologic recognition of the tumor. This lack of recognition might subsequently lead to low levels of tumor-infiltrating cells.
METHODS: To test this hypothesis, we determined the type and number of tumor-infiltrating cells in tumor sections from 24 uveal melanomas. We applied monoclonal antibodies directed against different types of immune cells and compared the results with the expression of HLA class I and class II antigens on the tumor cells.
RESULTS: Infiltrating immune cells were observed in all uveal melanomas (although in small amounts), with a predominance of T lymphocytes. Significant positive correlations were observed between the number of CD3+ cells (T lymphocytes) and monomorphic HLA class I expression, allele-specific HLA-A2 and Bw4 expression, and HLA class II expression. Furthermore, the number of CD4+ cells (T helper cells, monocytes/ macrophages) and of CD11b+ cells (monocytes/macrophages) was significantly correlated with the level of monomorphic HLA class I expression.
CONCLUSION: These data support our hypothesis that low levels of HLA expression (and therefore a lack of presentation of tumor-specific antigens) may lead to a low level of tumor infiltrate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8750848     DOI: 10.1007/bf00186516

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  40 in total

1.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

2.  A monoclonal antibody directed against the HLA-Bw6 epitope.

Authors:  S F Radka; D D Kostyu; D B Amos
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

3.  The prognostic significance of lymphocytic infiltration in malignant melanoma of the choroid.

Authors:  J R Lang; F H Davidorf; N Baba
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

4.  Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer.

Authors:  F Momburg; T Degener; E Bacchus; G Moldenhauer; G J Hämmerling; P Möller
Journal:  Int J Cancer       Date:  1986-02-15       Impact factor: 7.396

5.  HLA class II antigen expression in human papillomavirus-associated cervical cancer.

Authors:  S S Glew; M Duggan-Keen; T Cabrera; P L Stern
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

6.  Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma.

Authors:  D J Ruiter; A K Bhan; T J Harrist; A J Sober; M C Mihm
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

7.  Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells.

Authors:  P G Natali; P Giacomini; A Bigotti; K Imai; M R Nicotra; A K Ng; S Ferrone
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

8.  Characterization of novel anti-tumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes.

Authors:  T L Whiteside; D S Heo; S Takagi; R B Herberman
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

9.  Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity.

Authors:  H H van Ravenswaay Claasen; P M Kluin; G J Fleuren
Journal:  Lab Invest       Date:  1992-08       Impact factor: 5.662

10.  Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma.

Authors:  B R Ksander; P E Rubsamen; K R Olsen; S W Cousins; J W Streilein
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-12       Impact factor: 4.799

View more
  25 in total

1.  Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma.

Authors:  Pierre L Triozzi; Wayne Aldrich; Arun Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-25       Impact factor: 4.799

2.  Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration.

Authors:  Long V Ly; Inge H G Bronkhorst; Els van Beelen; Johannes Vrolijk; Andrew W Taylor; Mieke Versluis; Gregorius P M Luyten; Martine J Jager
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

3.  Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.

Authors:  Sudha Neelam; Jessamee Mellon; Amber Wilkerson; Jerry Y Niederkorn
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

Review 4.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 5.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

6.  HLA expression in a primary uveal melanoma, its cell line, and four of its metastases.

Authors:  D J Blom; L R Schurmans; I De Waard-Siebinga; D De Wolff-Rouendaal; J E Keunen; M J Jager
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

Review 7.  Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Authors:  Kimberly M Komatsubara; Richard D Carvajal
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

Review 8.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

9.  Evidence of macrophage and lymphocyte, but not dendritic cell, infiltration in posterior uveal melanomas, whilst cultured uveal melanomas demonstrate pluripotency by expressing CD68 and CD163.

Authors:  Julia Woodward; Karen Sisley; Graham Reeves; Carmel Nichols; M Andrew Parsons; Hardeep Mudhar; Ian Rennie
Journal:  Int J Exp Pathol       Date:  2004-02       Impact factor: 1.925

10.  M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles.

Authors:  Martina C Herwig; Chris Bergstrom; Jill R Wells; Tobias Höller; Hans E Grossniklaus
Journal:  Exp Eye Res       Date:  2012-11-30       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.